Offer Erez1,2, Roberto Romero1,3,4,5, Edi Vaisbuch1,2, Nandor Gabor Than1,2,6,7,8, Juan Pedro Kusanovic1,9,10, Shali Mazaki-Tovi1,2, Francesca Gotsch1,11, Pooja Mittal1,2, Zhong Dong1,2, Tinnakorn Chaiworapongsa1,2, Chong Jai Kim1,12, Chia-Ling Nhan-Chang1,2,13, Sun Kwon Kim1,2, Lami Yeo1,2, Moshe Mazor14, Sonia S Hassan1,2. 1. a Perinatology Research Branch , NICHD/NIH/DHHS , Bethesda , MD, and Detroit, MI , USA. 2. b Department of Obstetrics and Gynecology , Wayne State University School of Medicine , Detroit , MI , USA. 3. c Department of Obstetrics and Gynecology , University of Michigan , Ann Arbor , MI , USA. 4. d Department of Epidemiology and Biostatistics , Michigan State University , East Lansing , MI , USA. 5. e Center for Molecular Medicine and Genetics , Wayne State University , Detroit , MI , USA. 6. f Maternity Private Department, Kutvolgyi Clinical Block , Semmelweis University , Budapest , Hungary. 7. g Systems Biology of Reproduction Lendulet Research Group , Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences , Budapest , Hungary. 8. h First Department of Pathology and Experimental Cancer Research , Semmelweis University , Budapest , Hungary. 9. i Department of Obstetrics and Gynecology, Center for Research and Innovation in Maternal-Fetal Medicine (CIMAF) , Sótero del Río Hospital , Santiago , Chile. 10. j Division of Obstetrics and Gynecology, Faculty of Medicine , Pontificia Universidad Católica de Chile , Santiago , Chile. 11. k Department of Obstetrics and Gynecology, Azienda , Ospedaliera Universitaria Integrata , Verona , Italy. 12. l Department of Pathology , University of Ulsan College of Medicine , Seoul , Republic of Korea. 13. m Department of Obstetrics and Gynecology , Columbia University , New York , NY , USA. 14. n Department of Obstetrics and Gynecology , Ben-Gurion University , Beer-Sheva , Israel.
Abstract
OBJECTIVE: The aim of this study was to determine whether the activity of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in the plasma of women with preeclampsia (PE) and small for gestational age (SGA) neonate differ from that of normal pregnant women and whether they are related to specific placental lesions. METHODS: This cross-sectional study included the following groups: (1) normal pregnancy (n = 68); (2) PE (n= 128); and (3) SGA (n = 56). Maternal plasma TF and TFPI activity was determined with chromogenic assays. RESULTS: (1) The median maternal plasma TF activity, but not TFPI activity, differed among the study groups (p < .0001 and p = .4, respectively); (2) patients with PE had a higher median maternal plasma TF activity than women with normal pregnancies (p < .0001) and mothers with SGA fetuses (p = .002); (3) among patients with PE, those with distal villous hypoplasia had a higher median maternal TF activity than those without these placental lesions (p = .018); and (4) following adjustment for confounding variables, maternal plasma TF and TFPI activity were not associated with an SGA neonate. CONCLUSIONS: Plasma TF activity is higher in women with PE than in those with SGA or normal pregnancies. We propose that these changes may be responsible, at least in part, for the increased in-vivo thrombin generation observed in this obstetrical syndrome.
OBJECTIVE: The aim of this study was to determine whether the activity of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in the plasma of women with preeclampsia (PE) and small for gestational age (SGA) neonate differ from that of normal pregnant women and whether they are related to specific placental lesions. METHODS: This cross-sectional study included the following groups: (1) normal pregnancy (n = 68); (2) PE (n= 128); and (3) SGA (n = 56). Maternal plasma TF and TFPI activity was determined with chromogenic assays. RESULTS: (1) The median maternal plasma TF activity, but not TFPI activity, differed among the study groups (p < .0001 and p = .4, respectively); (2) patients with PE had a higher median maternal plasma TF activity than women with normal pregnancies (p < .0001) and mothers with SGA fetuses (p = .002); (3) among patients with PE, those with distal villous hypoplasia had a higher median maternal TF activity than those without these placental lesions (p = .018); and (4) following adjustment for confounding variables, maternal plasma TF and TFPI activity were not associated with an SGA neonate. CONCLUSIONS: Plasma TF activity is higher in women with PE than in those with SGA or normal pregnancies. We propose that these changes may be responsible, at least in part, for the increased in-vivo thrombin generation observed in this obstetrical syndrome.
Authors: Luci Maria Sant'Ana Dusse; Maria das Graças Carvalho; Alan J Cooper; Bashir A Lwaleed Journal: Clin Chim Acta Date: 2006-05-19 Impact factor: 3.786
Authors: Charles J Lockwood; Graciela Krikun; Rebeca Caze; Mizanur Rahman; Lynn F Buchwalder; Frederick Schatz Journal: Ann N Y Acad Sci Date: 2008-04 Impact factor: 5.691
Authors: Angelika V Timofeeva; Ivan S Fedorov; Alexander G Brzhozovskiy; Anna E Bugrova; Vitaliy V Chagovets; Maria V Volochaeva; Natalia L Starodubtseva; Vladimir E Frankevich; Evgeny N Nikolaev; Roman G Shmakov; Gennady T Sukhikh Journal: Diagnostics (Basel) Date: 2021-04-20